

Low-Level Laser (Light) Therapy (LLLT) in Skin: Stimulating, Healing, Restoring

Pinar Avci, MD,^{*,†} Asheesh Gupta, PhD,^{*,†,‡} Magesh Sadasivam, MTech,^{*,†,§}
Daniela Vecchio, PhD,^{*,†} Zeev Pam, MD,^{¶,¶} Nadav Pam, MD,[¶] and Michael R. Hamblin, PhD^{*,†,§}

Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function. Although skin is naturally exposed to light more than any other organ, it still responds well to red and near-infrared wavelengths. The photons are absorbed by mitochondrial chromophores in skin cells. Consequently, electron transport, adenosine triphosphate nitric oxide release, blood flow, reactive oxygen species increase, and diverse signaling pathways are activated. Stem cells can be activated, allowing increased tissue repair and healing. In dermatology, LLLT has beneficial effects on wrinkles, acne scars, hypertrophic scars, and healing of burns. LLLT can reduce UV damage both as a treatment and as a prophylactic measure. In pigmentary disorders such as vitiligo, LLLT can increase pigmentation by stimulating melanocyte proliferation and reduce depigmentation by inhibiting autoimmunity. Inflammatory diseases such as psoriasis and acne can also be managed. The noninvasive nature and almost complete absence of side effects encourage further testing in dermatology.

Semin Cutan Med Surg 32:41-52 © 2013 Frontline Medical Communications

Increasingly, noninvasive therapies for skin disease and skin rejuvenation are being used, especially in Western countries, where relatively high disposable incomes are combined with the desire for an ideal appearance fostered by societal pressures. Although skin is the organ most exposed to light, it still responds well to red and near-infrared (NIR) wavelengths delivered at the correct parameters with therapeutic intent. Low-level laser therapy (LLLT) was discovered in the late 1960s, but only recently has it been widely applied in dermatology. The introduction of light-emitting diode (LED) devices has reduced many of the concerns formerly associated with lasers, such as expense, safety concerns, and the need for trained personnel to operate them. In fact, many

LED devices are designed for home use and are widely sold on the Internet. This review will cover the use of LLLT as possibly the ultimate noninvasive approach to treating the skin.

LLLT and Its Mechanism of Action

LLLT, phototherapy, or photobiomodulation refers to the use of photons at a nonthermal irradiance to alter biological activity. LLLT uses coherent light sources (lasers), noncoherent light sources consisting of filtered lamps or LED, or, on occasion, a combination of both. The main medical applications of LLLT are reducing pain and inflammation, augmenting tissue repair and promoting regeneration of different tissues and nerves, and preventing tissue damage in situations where it is likely to occur.^{1,2} In the past few decades, nonablative laser therapies have been used increasingly for the esthetic treatment of fine wrinkles, photoaged skin, and scars, a process known as photorejuvenation (Table 1). More recently, this approach has also been used for inflammatory acne (Table 1).³ LLLT involves exposing cells or tissue to low levels of red and NIR light. This process is referred to as “low level” because the energy or power densities used are low compared with other forms of laser therapy such as ablation,

*Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA.

†Department of Dermatology, Harvard Medical School, Boston, MA.

‡Defence Institute of Physiology and Allied Sciences, Delhi, India.

§Harvard-MIT Division, Health Sciences and Technology, Cambridge, MA.

¶Aripam Medical Center, Ashdod, Israel.

Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure for Potential Conflicts of Interest and none were reported.

Correspondence: Michael R. Hamblin, PhD, Department of Dermatology, Harvard Medical School, BAR 414 Wellman, Center for Photomedicine, Massachusetts General Hospital, 40 Blossom Street, Boston, MA 02114.
E-mail: hamblin@helix.mgh.harvard.edu

¹deceased.

Table 1 Examples of LLLT Devices for Dermatologic Applications

Supplier	Product Name	Wavelength (nm)	Power Density (mW/cm ²)	Standard Dose (J/cm ²)	Application
PhotoMedex (Manchester, UK)	Omnilux	415 (±5)	40	48	Acne, photodamage, nonmelanoma skin cancers, skin rejuvenation, vitiligo, and wound healing after elective surgery
		633 (±6)	105	126	
		830 (±5)	55	66	
Edge Systems (Signal Hill, CA)	Delphia del Sol	420 600-700 700-1000		7.4 J per treatment area	Acne, improving skin texture, firmness and resilience, increasing lymphatic system activity, fine lines, wrinkles, and superficial hyperpigmentation
Flip 4 (Sainte-Julie, Quebec, Canada)	Max7	420-700	≤4		Acne, rejuvenation and injured skin healing, including the shortening of the post-skin resurfacing erythema duration
Light BioSciences (Virginia Beach, VA)	Gentlewaves	588 (±10)	Variable		Antiaging
OPUSMED (Montreal, Canada)	LumiPhase-R	660	150		Skin firmness, rhytid depth, and wrinkles
Revitalight (Chicago, IL)	Revitalight 747 Hand Spa Food Spa Evolution	420	80	7.2 J per 90 s per treatment area	Fine lines, wrinkles, and age spots on the face, neck, and hands
		590	80		
		625	80		
		940	80		
Soli-Tone (Woburn, MA)	LumiFacial Lumilift	470	84		Acne, antiaging, hyperpigmentation, and rosacea
		525	27		
		590	10		
		640	89		
DUSA (Wilmington, MA)	BLU-U	417	10		Acne
Curelight (Rehovot, Israel)	iClearXL	405-420		60	Acne, antiaging, skin rejuvenation, acceleration of healing of post peel, and postsurgical suture sites
	Clear100XL	890-900			
Lumenis (Santa Clara, CA)	ClearLight Clear100	405-420	200	60	Acne
Lightwave Technologies (Phoenix, AZ)	Lightwave Professional Deluxe LED System	417 630 880			Antiaging and skin rejuvenation
Dynatronics (Salt Lake City, UT)	Synergie LT2	660 880	500 mW (total power)	6 J per treatment area	Antiaging, skin firmness, wrinkles, skin tone, and texture for face and neck

cutting, and thermally coagulating tissue. Recently, medical treatment with LLLT at various intensities has been found to stimulate or inhibit an assortment of cellular processes.⁴

The mechanism associated with the cellular photobiostimulation by LLLT is not yet fully understood. From observation, it appears that LLLT has a wide range of effects at the molecular, cellular, and tissue levels. The basic biological mechanism behind the effects of LLLT is thought to be through absorption of red and NIR light by mitochondrial chromophores, in particular cytochrome *c* oxidase (CCO), which is contained in the respiratory chain located within the mitochondria,⁵⁻⁷ and perhaps also by photoacceptors in the plasma membrane of cells. Consequently, a cascade of events occur in the mitochondria, leading to biostimulation of various processes (Fig. 1).⁸ Absorption spectra obtained for CCO in different oxidation states were recorded and found to be very similar to the action spectra for biological responses to the light.⁵ It is hypothesized that this absorption of light energy may cause photodissociation of inhibitory nitric oxide from CCO,⁹ leading to enhancement of enzyme activity,¹⁰ electron transport,¹¹ mitochondrial respiration, and adenosine triphosphate production (Fig. 1).¹²⁻¹⁴ In turn, LLLT alters the cellular redox state, which induces the activation of numerous intracellular signaling pathways, and alters the affinity of transcription factors concerned with cell proliferation, survival, tissue repair, and regeneration (Fig. 1).^{2,5,6,15,16}

Although LLLT is now used to treat a wide variety of ailments, it remains somewhat controversial as a therapy for 2 principal reasons. First, there are uncertainties about the fundamental molecular and cellular mechanisms responsible for

transducing signals from the photons incident on the cells to the biological effects that take place in the irradiated tissue. Second, there are significant variations in terms of dosimetry parameters: wavelength, irradiance or power density, pulse structure, coherence, polarization, energy, fluence, irradiation time, contact versus noncontact application, and repetition regimen. Lower dosimetric parameters can result in reduced effectiveness of the treatment, and higher ones can lead to tissue damage.¹ This illustrates the concept of the biphasic dose response that has been reported to operate in LLLT.^{1,17,18} Many of the published studies on LLLT include negative results. It is possibly because of an inappropriate choice of light source and dosage. It may also be due to inappropriate preparation of the patient's skin before application of LLLT, such as lack of removal of makeup and oily debris, which can interfere with the penetration of the light source, and failure to account for skin pigmentation.¹⁹ Inappropriate maintenance of the LLLT equipment can reduce its performance and interfere with clinical results as well. It is important to consider that there is an optimal dose of light for any particular application.

Laser radiation or noncoherent light has a wavelength- and radiant exposure-dependent capability to alter cellular behavior in the absence of significant heating.²⁰ Phototherapy uses light with wavelengths between 390 and 1100 nm and can be continuous wave or pulsed. In normal circumstances, it uses relatively low fluences (0.04-50 J/cm²) and power densities (<100 mW/cm²).²¹ Wavelengths in the range of 390-600 nm are used to treat superficial tissue, and longer wavelengths in the range of 600-1100 nm, which




Figure 1 Mechanism of action of LLLT. (Figure courtesy of Wellman Center for Photomedicine.)




Figure 2 Tissue penetration depths of various wavelengths. (Figure courtesy of Wellman Center for Photomedicine.)

penetrate further, are used to treat deeper-seated tissues (Fig. 2).⁴ Wavelengths in the range of 700-750 nm have been found to have limited biochemical activity and are therefore not often used.¹ Various light sources used in LLLT include inert gas lasers and semiconductor laser diodes such as helium neon (HeNe; 633 nm), ruby (694 nm), argon (488 and 514 nm), krypton (521, 530, 568, 647 nm), gallium arsenide (GaAs; >760 nm, with a common example of 904 nm), and gallium aluminum arsenide (GaAlAs; 612-870 nm).¹⁹ A wide range of LED semiconductors are available at lower wavelengths, the medium of which contains the elements indium, phosphide, and nitride. One question that has not yet been conclusively answered is whether there is any advantage to using coherent laser light over noncoherent LED light.²² Although some medical practitioners treat deep tissue lesions using focused lasers in “points,” in dermatology, the use of LEDs is becoming increasingly common owing to the relatively large areas of tissue that require irradiation.

LLLT for Skin Rejuvenation

Skin starts showing its first signs of aging in the late 20s to early 30s, and it usually presents with wrinkles, dyspigmentation, telangiectasia, and loss of elasticity. Common histologic and molecular-level features are reduction in the amount of collagen, fragmentation of collagen fibers, elastotic degeneration of elastic fibers, upregulation of matrix metalloproteinases (MMPs), especially MMP-1 and MMP-2, dilated and tortuous dermal vessels, and atrophy and disorientation of the epidermis.^{23,24} Both chronological and environmental influences are responsible for the aging process of skin; however, photodamage seems to be one of the most important causes of these changes.

Several modalities have been developed to reverse the dermal and epidermal signs of photo- and chronological aging. The main concept of most of these modalities is removing the epidermis and inducing a controlled form of skin wounding to promote collagen biosynthesis and dermal matrix remodeling. The most commonly used interventions as of today are retinoic acid (a vitamin A derivative) therapy, dermabrasion, chemical peels, and ablative laser resurfacing with carbon dioxide (CO₂) or erbium:yttrium-aluminum-garnet (Er:YAG) lasers or a combination of these wavelengths.²⁵⁻²⁷ However, these procedures require intensive posttreatment care and prolonged downtime, and may lead to complications such as long-lasting erythema, pain, infection, bleeding, oozing, burns, hyper- or hypopigmentation, and scarring.^{28,29} These limitations created a need for the development of alternative rejuvenation procedures that were safer and more effective, had fewer side effects, and required minimum postoperative care and downtime, which in turn led to the emergence of nonablative rejuvenation technologies.³⁰⁻³² Nonablative skin rejuvenation aims to improve photoaged and aging skin without destroying the epidermis.^{31,32} Irregular pigmentation and telangiectasia can be treated with intense pulsed light sources, 532-nm potassium-titanyl-phosphate lasers, and high-dose 585/595-nm pulsed dye lasers.³³ Wrinkle reduction and skin tightening through thermal injury to the dermis (photothermolysis) can be achieved by other intense pulsed light sources (ie, low-dose 589/595-nm pulsed dye lasers, 1064- and 1320-nm neodymium:yttrium-aluminum-garnet lasers [Nd:YAG], 1450-nm diode lasers, and 1540-nm erbium fiber lasers).³³

LED, which is a novel light source for nonthermal nonablative skin rejuvenation, has been shown to be effective for improving wrinkles and skin laxity.³⁴⁻⁴⁰ It is not a new phe-




Figure 3 Possible mechanism of actions for LLLT's effects on skin rejuvenation. LLLT aids skin rejuvenation through increasing collagen production and decreasing collagen degradation. Increase in collagen production occurs by LLLT's increasing effects on PDGF and fibroblast production, which happens through decreasing apoptosis and increasing vascular perfusion and bFGF and TGF- β expressions. Decrease in IL-6 and increase in TIMPs, which in turn reduce MMPs, aid in reduction of collagen degradation. (Figure courtesy of Wellman Center for Photomedicine.)

nomenon because the first reports of LLLT effects on increased collagen go back to 1987. Studies by Abergel et al and Yu et al reported an increase in production of procollagen, collagen, and basic fibroblast growth factors (bFGF), as well as proliferation of fibroblasts after exposure to low-energy laser irradiation in *in vitro* and *in vivo* animal models (Fig. 3).^{41,42} Furthermore, LLLT was already known to increase microcirculation and vascular perfusion in the skin, alter platelet-derived growth factor (PDGF) and transforming growth factor (TGF- β 1) expressions, and inhibit apoptosis (Fig. 3).^{1,43,44} Lee et al investigated the histologic and ultrastructural changes after a combination of 830-nm, 55-mW/cm², 66-J/cm² and 633-nm, 105-mW/cm², and 126-J/cm² LED phototherapy and observed alteration in the status of MMPs and their tissue inhibitors (TIMPs).³³ Furthermore, mRNA levels of interleukin (IL)-1 β , tumor necrosis factor- α (TNF- α), intercellular adhesion molecule 1 (ICAM-1), and connexin 43 were increased after LED phototherapy, whereas IL-6 levels were decreased (Fig. 3).³³ Finally, an increase in the amount of collagen was demonstrated in the posttreatment specimens.³³ Proinflammatory cytokines IL-1 β and TNF- α are thought to be recruited to heal the intentionally formed photothermally mediated wounds associated with laser treatments, and this cascade of wound healing consequently contributes to new collagen synthesis.³³ LED therapy may induce this wound healing process through nonthermal and atraumatic induction of a subclinical "quasi-wound," even without any actual thermal damage, which could cause complications as in some other laser treatments.³³ TIMPs inhibit MMP activities, so another possible mechanism for the increased collagen could be through the induction of TIMPs (Fig. 3). When these observations are put together, it is possible that increased production of IL-1 β and

TNF- α might have induced MMPs in the early response to LED therapy. This may clear the photodamaged collagen fragments to enable biosynthesis of new collagen fibers. Later, an increase in the amount of TIMPs might protect the newly synthesized collagen from proteolytic degradation by MMPs.³³ Furthermore, increased expression of connexin 43 may possibly enhance cell-to-cell communication between dermal components, especially the fibroblasts, and enhance the cellular responses to the photobiostimulation effects from LED treatment, to produce new collagen in a larger area that even includes the nonirradiated regions.³³ In a clinical study performed by Weiss et al, 300 patients received LED therapy (590 nm, 0.10 J/cm²) alone, and 600 patients received LED therapy in combination with a thermal-based photorejuvenation procedure. Among patients who received LED photorejuvenation alone, 90% reported that they observed a softening of skin texture and a reduction in roughness and fine lines, ranging from a significant reduction to sometimes subtle changes.³⁶ Moreover, patients receiving a thermal photorejuvenation laser with or without additional LED photomodulation (n = 152) reported a prominent reduction in posttreatment erythema and an overall impression of increased efficacy with the additional LED treatment.^{36,45} This reduction in posttreatment erythema could be attributed to anti-inflammatory effects of LLLT.⁴⁰ Using different pulse sequence parameters, a multicenter clinical trial was conducted, with 90 patients receiving 8 LED treatments over 4 weeks.^{37,46-48} The outcome of this study showed very favorable results, with >90% of patients improving by at least one Fitzpatrick photoaging category and 65% of patients demonstrating global improvement in facial texture, fine lines, background erythema, and pigmentation. The results peaked at 4-6 months after completion of 8 treatments. Markedly in-




Figure 4 Illustration of acne treatment with red and blue light. When used in combination, red light and blue light have synergistic effects in treatment of acne. *Propionibacterium acnes* synthesizes and stores a large amount of porphyrins. Once the porphyrin is exposed to visible light (specifically blue light), it becomes chemically active and transfers to an excited state, resulting in formation of reactive free radicals and singlet oxygen, which in turn causes membrane damage in *P. acnes*.^{49,53} Red light is proposed to exert its effects through reducing the inflammatory process.^{51,54} (Figure courtesy of Wellman Center for Photomedicine.)

creased collagen in the papillary dermis and reduced MMP-1 were common findings. Barolet et al's study is also consistent with the previously mentioned studies. They used a 3D model of tissue-engineered human reconstructed skin to investigate the potential of 660-nm, 50-mW/cm², 4-J/cm² LED in modulating collagen and MMP-1, and results showed up-regulation of collagen and downregulation MMP-1 in vitro.⁴⁰ A split-face single-blinded clinical study was then carried out to assess the results of this light treatment on skin texture and appearance of individuals with aged/photoaged skin.⁴⁰ After 12 LED treatments, profilometry quantification demonstrated that >90% of individuals had a reduction in rhytid depth and surface roughness, and 87% reported that they have experienced a reduction in the Fitzpatrick wrinkling severity score.⁴⁰

LLLT for Acne

Pathogenesis of acne vulgaris has not yet been clarified; however, current consensus is that it involves 4 main events: follicular hyperconification, increased sebum secretion effected by the androgenic hormone secretions, colonization of *Propionibacterium acnes*, and inflammation.⁴⁹ *P. acnes* plays a key role by acting on triglycerides and releasing its cytokines, which in turn trigger inflammatory reactions and alter infundibular keratinization.⁴⁹ Current treatments for acne vulgaris include topical and oral medications such as topical antibiotics, topical retinoids, benzoyl peroxide, alpha hydroxy acids, salicylic acid, or azelaic acid. In severe cases, systemic antibiotics such as tetracycline and doxycycline, oral retinoids, and some hormones are indicated.⁵⁰ Medications work by counteracting microcomedone formation, sebum production, *P. acnes* metabolism, and inflammation.⁵⁰

Despite many options that are available for treatment of acne vulgaris, many patients still respond inadequately to treatment or experience some adverse effects.

Phototherapy (light, lasers, and photodynamic therapy) has been proposed as an alternative therapeutic modality to treat acne vulgaris and was proposed to have fewer side effects compared with other treatment options.⁵¹ Exposure of sunlight was reported to be highly effective for treatment of acne, with efficacy up to 70%.⁵² The sunlight decreases the androgenic hormones in the sebaceous gland, but the unwanted effect of exposure to UVA and UVB limits sunlight for the treatment of acne. Recently, phototherapy with visible light (mainly blue light, red light, or combination of both) has been used in the treatment of acne.⁵² One mechanism of action of phototherapy for acne is through the absorption of light (specifically blue light) by porphyrins that have been produced by *P. acnes* as a part of its normal metabolism, and that act as endogenous photosensitizers.^{49,53} This process causes a photochemical reaction and forms reactive free radicals and singlet oxygen species, which in turn lead to bacterial destruction (Fig. 4).^{49,53} Red light is known to penetrate deeper in tissues when compared with blue light.⁵⁰ It has been demonstrated that red light can affect the sebum secretion of sebaceous glands and change keratinocyte behavior.⁵⁴ Furthermore, red light might also exert its effects by modulating cytokines from macrophages and other cells, which in turn could reduce inflammation.^{51,54}

Several studies reported that LLLT in the red to NIR spectral range (630-1000 nm) and nonthermal power (<200 mW) alone or in combination with other treatment modalities (mainly blue light) is effective for treatment of acne vulgaris.^{17,49,52,54,55} One of these studies demonstrated significant reduction in active acne lesions after 12 sessions of

treatment using 630-nm red-spectrum LLLT, with a fluence of 12 J/cm², twice a week, in conjunction with 2% topical clindamycin; however, the same study showed no significant effects when an 890-nm laser was used.⁵⁰ A few studies also showed that the combination of blue light and red light has synergistic effects in acne treatment.^{49,54-56} It is proposed that synergistic effects of mixed light are due to synergy between the antibacterial and anti-inflammatory effect of blue and red light, respectively (Fig. 4).^{49,56} It is also worth mentioning that in most studies, improvement in inflammatory lesions was higher than the improvement in comedones.^{49,56}

LLLT for Photoprotection

It is widely accepted that the UV range (<400 nm) exposure is responsible for almost all damaging photoinduced effects on human skin.⁵⁷⁻⁵⁹ Some proposed mechanisms for UV-induced skin damage are collagen breakdown, formation of free radicals, inhibition of DNA repair, and inhibition of the immune system.⁵⁷⁻⁵⁹ Existing solutions to prevent UV-induced damaging effects are based on minimizing the amount of UV irradiation that reaches the skin, which is achieved by either avoidance of sun exposure or use of sunscreens. However, sometimes sun avoidance might be hard to implement, especially for the people involved in outdoor occupations or leisure activities. In contrast, the photoprotective efficacy of topical sunscreens has limitations as well, which include decreased efficacy after water exposure or perspiration, spectral limitations, possible toxic effects of nanoparticles that are contained by most sunscreens,⁶⁰ user allergies, and compliance.

It has recently been suggested that infrared (IR) exposure might have protective effects against UV-induced skin damage mainly by triggering protective/repair responses to UV irradiation. In the natural environment, visible and IR solar wavelengths predominate in the morning, and UVB and UVA are maximal around noon, which suggests that mammals already possess a natural mechanism that, in reaction to morning IR radiation, prepares the skin for upcoming potentially damaging UV radiation at noon.⁶¹ However, opposing views also exist, such as Krutmann and Schroeder's study demonstrating IR-induced disturbance of the electron flow of the mitochondrial electron transport chain, which leads to inadequate energy production in dermal fibroblasts.⁶² Schroeder et al's report is another example stating that IR alters the collagen equilibrium of the dermal extracellular matrix (ECM) by leading to an increased expression of the collagen-degrading enzyme MMP-1, and by decreasing the *de novo* synthesis of the collagen itself.⁵⁹ As previously mentioned, the same light source may have opposite effects on the same tissue, depending on the parameters used, and these conflicting views are probably due to the biphasic effects of light.^{17,18}

Menezes et al demonstrated that noncoherent NIR (700-2000 nm) generated a strong cellular defense against solar UV cytotoxicity in the absence of rising skin temperature, and it was assumed to be a long-lasting (at least 24 h) and cumulative phenomenon.⁶³ Following this study, Frank et al proposed that IR irradiation prepares cells to resist UVB-

induced damage by affecting the mitochondrial apoptotic pathway.⁶⁴ IR preirradiation of human fibroblasts was shown to inhibit UVB activation of caspase-9 and -3, partially release cytochrome *c* and Smac/DIABLO, decrease proapoptotic proteins (ie, Bax), and increase antiapoptotic proteins (ie, Bcl-2 or Bcl-xL).⁶⁴ The results suggested that IR inhibited UVB-induced apoptosis by modulating the Bcl-2/Bax balance, pointing to a role of p53, a sensor of gene integrity involved in cell apoptosis and repair mechanisms. In a further study, Frank et al studied more specifically the role of the p53 cell signaling pathway in the prevention of UVB toxicity.⁶⁴ The response to IR irradiation was shown to be p53 dependent, which further suggests that IR irradiation prepares cells to resist and/or to repair further UVB-induced DNA damage. Finally, the IR induction of defense mechanisms was supported by Applegate et al, who reported that the protective protein, ferritin, normally involved in skin repair (scavenger of Fe²⁺ otherwise available for oxidative reactions) was induced by IR radiation.⁶⁵

In an *in vitro* study, it was reported that an increase in dermal fibroblast procollagen secretion reduces MMP or collagenase production after nonthermal noncoherent deep red visible LED exposures (660 nm, sequential pulsing mode).⁴⁰ These results correlated with significant clinical improvement of rhytids *in vivo*.⁴⁰ In a subsequent *in vivo* pilot study, effect of this wavelength in 3 healthy subjects using a minimal erythral dose method adapted from sunscreen sun protection factor (SPF) determination has been investigated.⁶¹ The results showed that LED therapy was effective, achieving a significant response in the reduction of the erythema induced by UVB.⁶¹ Following this pilot study, a further investigation has been performed to find out *in vivo* aspects of this phenomenon. Effects of nonthermal noncoherent 660-nm LED pulsed treatments in providing enhanced skin resistance before upcoming UV damage were investigated in a group of subjects with normal fair skin and patients presenting with polymorphous light eruption. Results suggested that LED-based therapy before UV exposure provided significant dose-related protection against UVB-induced erythema. A significant reduction in UVB-induced erythema reaction was observed in at least one occasion in 85% of subjects as well as in the patients suffering from polymorphous light eruption. Furthermore, an SPF-15-like effect and a reduction in postinflammatory hyperpigmentation were observed. An *in vitro* study by Yu et al revealed that HeNe laser irradiation stimulated an increase in nerve growth factor (NGF) release from cultured keratinocytes and its gene expression.⁶⁶ NGF is a major paracrine maintenance factor for melanocyte survival in skin.⁶⁷ It was shown that NGF can protect melanocytes from UV-induced apoptosis by upregulating Bcl-2 levels in the cells.⁶⁸ Therefore, an increase in NGF production induced by HeNe laser treatment may provide another explanation for the photoprotective effects of LLLT.

LLLT for Herpes Virus Lesions

One of the most common virus infections is caused by herpes simplex virus (HSV). HSV is chronic and lasts one's entire

life. The exposure of the host to several kinds of physical or emotional stresses such as fever, exposure to UV light, and immune suppression causes virus reactivation and migration through sensory nerves to skin and mucosa, localizing particularly on the basal epithelium of the lips and the perioral area.⁶⁹ Up to 60% of sufferers will experience a prodromic stage, after which the lesions develop through stages of erythema, papule, vesicle, ulcer, and crust, until healing is achieved. It is accompanied by pain, burning, itching, or tingling at the site where the blisters form. Immune responses to HSV infection involve macrophages, Langerhans cells, natural killer cells, lymphocyte-mediated delayed-type hypersensitivity, and cytotoxicity.⁷⁰

Although several antiviral drugs such as acyclovir and valacyclovir are used to control recurrent herpes outbreaks, only limited reduction in the lesions' healing time has been observed.⁶⁹ Furthermore, development of drug-resistant HSV strains is of increasing significance, especially in immunocompromised patients.⁷⁰ Therefore, new therapy modalities that can shorten the recurrent episodes and cause prominent reduction of related pain and inflammation are necessary.

LLLT has been suggested as an alternative to current medications for accelerated healing, reducing symptoms, and influencing the length of the recurrence period.^{69,71,72} Among 50 patients with recurrent perioral HSV infection (at least once per month for >6 months), when LLLT (690 nm, 80 mW/cm², 48 J/cm²) was applied daily for 2 weeks during recurrence-free periods, it was shown to decrease the frequency of herpes labialis episodes.⁷³ In another study with similar irradiation parameters (647 nm, 50 mW/cm², 4.5 J/cm²), investigators achieved a significant prolongation of remission intervals from 30 to 73 days in patients with recurrent HSV infection.⁷⁴ Interestingly, patients with labial herpes infection showed better results than those with genital infection. However, irradiation did not affect established HSV latency in a murine model.⁷⁵

Although mechanism of action is still not clear, an indirect effect of LLLT on cellular and humoral components of the immune system involved in antiviral responses rather than a direct virus-inactivating effect was proposed.⁷⁶ Inoue et al investigated tuberculin reactions at the bilateral sites of the backs of sensitized guinea pigs. They applied a single low-power laser irradiation dose at a fluence of 3.6 J/cm² on one side and compared it with contralateral nonirradiated sites.⁷⁷ Interestingly, after irradiation, tuberculin reaction was suppressed not only at the irradiated site but also at the contralateral nonirradiated site. It is worth noting that this phenomenon was observed when mononuclear cells were dominant in the perivascular cellular infiltration. Based on their results, they have suggested a possible systemic inhibitory effect of LLLT on delayed hypersensitivity reactions.⁷⁷ Activation and proliferation of lymphocytes⁷⁸⁻⁸¹ and macrophages,⁸² as well as the synthesis and expression of cytokines^{83,84} after low intensities of red and NIR light, have been reported by several investigators. The question of whether these effects of LLLT have any influence on HSV infection remains to be determined.

LLLT for Vitiligo

Vitiligo is an acquired pigmentary disorder characterized by depigmentation of the skin and hair. The underlying mechanism of how the functional melanocytes disappear from the involved skin is still under investigation. However, findings suggest that regardless of the pathogenetic mechanism involved, keratinocytes, fibroblasts, melanoblasts, and melanocytes may be involved in both the depigmentation and also the repigmentation processes of vitiligo.^{66,85-89} Therefore, stimulation of these epidermal and dermal cells may be a possible treatment option. Owing to the obscure pathogenesis of the disease, treatment of vitiligo has generally been unsatisfactory. Current existing therapies that induce varying degrees of repigmentation in patients with vitiligo are topical corticosteroids, phototherapy, and photochemotherapy (PUVA).⁸⁹ In 1982, a group of investigators found that low-energy laser irradiation had effects on defective biosynthesis of catecholamine in certain dermatologic conditions, including scleroderma and vitiligo.^{90,91} Later, one of the investigators from the same group reported that after 6-8 months of treating 18 vitiligo patients with low-energy HeNe laser (632 nm, 25 mW/cm²) therapy, marked repigmentation was observed in 64% of the patients, and some follicular repigmentation was observed in the remaining 34%.⁹¹ Since then, LLLT has been suggested as an alternative effective treatment option for patients with vitiligo.^{66,88,89}

Segmental-type vitiligo is associated with a dysfunction of the sympathetic nerves in the affected skin, and it is relatively resistant to conventional therapies.⁶⁶ Based on the previous reports stating that HeNe laser irradiation leads to improvement in nerve injury⁹²⁻⁹⁴ and LLLT induces repigmentation responses,^{95,96} it was proposed that the HeNe laser might be a potential treatment modality for treatment of segmental-type vitiligo.⁶⁶ When the HeNe laser light was administered locally (3 J/cm², 1.0 mW, 632.8 nm), marked perilesional and perifollicular repigmentation (>50%) was observed in 60% of patients with successive treatments. Both NGF and bFGF stimulate melanocyte migration, and deficiencies of these mediators may participate in the development of vitiligo.^{86,97,98} In the same study, when cultured keratinocytes and fibroblasts were irradiated with a 0.5- to 1.5-J/cm² HeNe laser, a significant increase in bFGF release both from keratinocytes and fibroblasts, as well as a significant increase in NGF release from keratinocytes, was reported.⁶⁶ Additionally, the medium from HeNe laser-irradiated keratinocytes stimulated [³H]thymidine uptake and proliferation of cultured melanocytes. Another study by Lan et al demonstrated that the HeNe laser (632.8 nm, 1 J/cm², and 10 mW) stimulates melanocyte proliferation through enhanced $\alpha 2\beta 1$ integrin expression⁸⁸ and induces melanocyte growth through upregulation of the expression of phosphorylated cyclic-adenosine monophosphate response element-binding protein, which is an important regulator of melanocyte growth.⁸⁸ ECM molecules are also important elements of the pigmentation process owing to their regulatory roles for physiological functions of pigment cells, including morphology, migration, tyrosinase activity, and proliferation.⁹⁹⁻¹⁰¹

Type IV collagen is present in the basement membrane and is known to have an intricate relationship with melanocytes in the epidermis, such as increasing melanocyte mobility.⁸⁹ After HeNe irradiation, the attachment of melanocytes to type IV collagen was found to be significantly enhanced, which also indicated modulation of melanocyte physiological function by HeNe laser irradiation.⁸⁸ Furthermore, among various ECM proteins found in the dermis, fibronectin was shown to have significant effects on both differentiation and migration of cultured melanoblasts and melanocytes.^{102,103} In 1983, Gibson et al demonstrated that the physical distribution of fibronectin in vivo was closely associated with the migration path undertaken by melanoblasts during the repigmentation process of vitiligo.¹⁰⁴ Based on Lan et al's findings, an immature melanoblast cell line (NCCmelb4) showed significant decrease in the attachment to fibronectin after HeNe laser treatment, whereas the attachment of a more differentiated melanoblast cell line (NCCmelan5) to fibronectin increased approximately 20% after 1-J/cm² 10-mW HeNe laser treatment.⁸⁹ Lastly, expression of integrin $\alpha 5\beta 1$, which mediates locomotion of pigment cells, was found to be enhanced on NCCmelb4 cells.⁸⁹

LLLT for Producing Depigmentation

Most studies carried out for vitiligo show the stimulatory effects of LLLT on pigmentation; however, in a previously mentioned study, while testing effects of blue and red laser for acne treatment, an interesting and unexpected result was found for the first time.⁴⁹ Combining both blue (415 ± 5 nm, irradiance: 40 mW/cm², 48 J/cm²) and red (633 ± 6 nm, 80 mW/cm², 96 J/cm²) light produced an overall decrease in the melanin level. Instrumental measurement results showed that melanin level increased by 6.7 (the median of differences between the melanin level before and after 1 treatment session) after blue light irradiation, without a statistical significance ($P > 0.1$), whereas it decreased by 15.5, with statistical significance ($P < 0.005$), after red light irradiation. This finding may have some relationship with the laser's brightening effect of the skin tone, which 14 of 24 patients spontaneously reported after the treatment period. However, as of today, no other studies investigated or reported a similar decrease in melanin levels after red light irradiation. Considering that different parameters are used for vitiligo and acne treatment, different effects of red light on the same tissue might be due to the biphasic effects of LLLT.^{18,19}

LLLT for Hypertrophic Scars and Keloids

Hypertrophic scars and keloids are benign skin tumors that usually form after surgery, trauma, or acne and are difficult to eradicate. Fibroblastic proliferation and excess collagen deposits are the 2 main characteristics,¹⁰⁵ and imbalance between rates of collagen biosynthesis and degradation superimposed on the individual's genetic predisposition has been

implicated in their pathogenesis. A wide range of surgical (eg, cryotherapy, excision), nonsurgical (eg, pharmacologic, mechanical pressure, silicone gel dressings), and laser therapies (CO₂, pulsed dye, fractional ablative, and nonablative lasers) have been tested, with variable success; however, until now, an optimal treatment of these lesions remains to be found.¹⁰⁶⁻¹⁰⁸ It has recently been proposed that poor regulation of IL-6 signaling pathways and TGF- $\beta 1$ expression have a significant role in this process, and thus inhibition of the IL-6 pathway and/or TGF- $\beta 1$ expression could be a potential therapeutic target.^{106,107,109-111} Based on the reports demonstrating the role of LLLT in decreasing IL-6 mRNA levels³³ and modulation of PDGF, TGF- β , ILs such as IL-13 and IL-15, and MMPs, which are also associated with abnormal wound healing,^{112,113} it was proposed to be an alternative therapy to existing treatment options. The use of LLLT as a prophylactic method to alter the wound healing process to avoid or attenuate the formation of hypertrophic scars or keloids has been investigated by Barolet and Boucher in 3 case studies, where after scar revision by surgery or CO₂ laser ablation on bilateral areas, a single scar was treated daily by the patient at home with 805-nm NIR-LED at 30 mW/cm² and 27 J/cm².¹¹² The first patient had preauricular linear keloids bilaterally after a face lift procedure and surgical scar revision/excision had been performed. The second patient had hypertrophic scars on the chest bilaterally after acne, for which the CO₂ laser was used for resurfacing. The third patient had hypertrophic scars on the back bilaterally after excision, and again the CO₂ laser was used for resurfacing. As a result, significant improvements in the NIR-LED-treated versus the control scar were seen in all efficacy measures; moreover, no significant treatment-related adverse effects were reported.¹¹²

LLLT for Burns

In a clinical study by Weiss et al, 10 patients received LED treatment (590 nm) for acute sunburn using a once- or twice-daily treatment regimen for 3 days, treating only half of the affected anatomic area.³⁶ Decreased symptoms of burning, redness, swelling, and peeling were reported. One patient received LED treatment twice daily for 3 days only on half of his back, and the other half was left untreated.³⁶ When compared with the untreated side, decreased MMP-1 was demonstrated on the LED-treated side through immunofluorescence staining. Moreover, RT-PCR gene expression analysis showed a significant decrease in MMP-1 gene expression on the LED-treated side at both 4 and 24 hours after UV injury compared with the untreated side. Other significant changes were also noted with LED treatment related to inflammation and dermal matrix composition 4 days after UV exposure.³⁶

One of the main complications of receiving laser treatment is burns, which may be devastating for the patient. LED was suggested as a treatment modality for facilitating faster healing. A group of 9 patients who had a variety of second-degree burns from nonablative laser devices was given LED therapy once a day for 1 week, and according to both the patient and the physician, healing occurred 50% faster.³⁶ Also, the same

investigators conducted a pilot study, where one forearm was injured by a CO₂ laser using a computer pattern generator to deliver the identical treatment to both test sites. Both sites received daily dressing changes using a nonstick dressing and Polysporin ointment (Johnson & Johnson Inc., Canada), but one site also received additional LED treatment.³⁶ As a result, when compared with the untreated control site, accelerated re-epithelialization was observed in the LED-treated site.³⁶

LLLT for Psoriasis

More recently, LLLT has been considered for treatment of plaque psoriasis. A recent preliminary study investigated the efficacy of a combination of 830 nm (NIR) and 630 nm (visible red light) to treat recalcitrant psoriasis using LED irradiation. All patients with psoriasis resistant to conventional therapy were enrolled and treated sequentially with 830- and 630-nm wavelengths in two 20-minute sessions, with 48 hours between sessions, for 4 or 5 weeks. The results showed no adverse side effects and a resolution of psoriasis.¹¹⁴ The limitation of this study was the small number of patients enrolled; however, the results observed encourage future investigations for use of LLLT in treating psoriasis.

Conclusions

LLLT appears to have a wide range of applications in dermatology, especially in indications where stimulation of healing, reduction of inflammation, reduction of cell death, and skin rejuvenation are required. The application of LLLT to disorders of pigmentation may work both ways by producing both repigmentation of vitiligo and depigmentation of hyperpigmented lesions, depending on the dosimetric parameters. The introduction of LED array-based devices has simplified the application to large areas of skin. There is no agreement as yet on several important parameters, particularly whether red, NIR, or a combination of both wavelengths is optimal for any particular application. There is a credibility gap that needs to be overcome before LLLT is routinely applied in every dermatologist's office.

Acknowledgments

This work was supported by the US NIH (R01AI050875 to MRH).

Dr Asheesh Gupta has received a grant from Boycast Fellowship, Rolo 11, in India.

References

- Chung H, Dai T, Sharma SK, et al. The nuts and bolts of low-level laser (light) therapy. *Ann Biomed Eng*. 2012;40:516-533.
- Gupta A, Avci P, Sadasivam M, et al. Shining light on nanotechnology to help repair and regeneration. *Biotechnol Adv*. (in press).
- Seaton ED, Mouser PE, Charakida A, et al. Investigation of the mechanism of action of nonablative pulsed-dye laser therapy in photorejuvenation and inflammatory acne vulgaris. *Br J Dermatol*. 2006;155:748-755.
- Barolet D. Light-emitting diodes (LEDs) in dermatology. *Semin Cutan Med Surg*. 2008;27:227-238.
- Karu TI, Kolyakov SF. Exact action spectra for cellular responses relevant to phototherapy. *Photomed Laser Surg*. 2005;23:355-361.
- Greco M, Guida G, Perlino E, et al. Increase in RNA and protein synthesis by mitochondria irradiated with helium-neon laser. *Biochem Biophys Res Commun*. 1989;163:1428-1434.
- Karu TI, Pyatibrat LV, Kalendo GS. Photobiological modulation of cell attachment via cytochrome *c* oxidase. *Photochem Photobiol Sci*. 2004;3:211-216.
- Oron U. Light therapy and stem cells: A therapeutic intervention of the future?. *J Interv Cardiol*. 2011;3:627-629.
- Lane N. Cell biology: Power games. *Nature*. 2006;443:901-903.
- Wong-Riley MT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: Role of cytochrome *c* oxidase. *J Biol Chem*. 2005;280:4761-4771.
- Pastore D, Greco M, Petragallo VA, et al. Increase in $<-H+/e->$ ratio of the cytochrome *c* oxidase reaction in mitochondria irradiated with helium-neon laser. *Biochem Mol Biol Int*. 1994;34:817-826.
- Karu T, Pyatibrat L, Kalendo G. Irradiation with He-Ne laser increases ATP level in cells cultivated in vitro. *J Photochem Photobiol B*. 1995;27:219-223.
- Karu T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. *J Photochem Photobiol B*. 1999;49:1-17.
- Harris DM. Editorial comment biomolecular mechanisms of laser biostimulation. *J Clin Laser Med Surg*. 1991;9:277-280.
- Liu H, Colavitti R, Rovira II, et al. Redox-dependent transcriptional regulation. *Circ Res*. 2005;97:967-974.
- Peplow PV, Chung TY, Ryan B, et al. Laser photobiomodulation of gene expression and release of growth factors and cytokines from cells in culture: A review of human and animal studies. *Photomed Laser Surg*. 2011;29:285-304.
- Huang YY, Sharma SK, Carroll J, et al. Biphasic dose response in low level light therapy—An update. *Dose Response*. 2011;9:602-618.
- Huang YY, Chen AC, Carroll JD, et al. Biphasic dose response in low level light therapy. *Dose Response*. 2009;7:358-383.
- Posten W, Wrona DA, Dover JS, et al. Low-level laser therapy for wound healing: Mechanism and efficacy. *Dermatol Surg*. 2005;31:334-340.
- Basford JR. Low intensity laser therapy: Still not an established clinical tool. *Lasers Surg Med*. 1995;16:331-342.
- AlGhamdi KM, Kumar A, Moussa NA. Low-level laser therapy: A useful technique for enhancing the proliferation of various cultured cells. *Lasers Med Sci*. 2012;27:237-249.
- Hode L. The importance of the coherency. *Photomed Laser Surg*. 2005;23:431-434.
- Kligman LH. Photoaging. Manifestations, prevention, and treatment. *Clin Geriatr Med*. 1989;5:235-251.
- Takema Y, Yorimoto Y, Kawai M, et al. Age-related changes in the elastic properties and thickness of human facial skin. *Br J Dermatol*. 1994;131:641-648.
- Branham GH, Thomas JR. Rejuvenation of the skin surface: Chemical peel and dermabrasion. *Facial Plast Surg*. 1996;12:125-133.
- Airan LE, Hruza G. Current lasers in skin resurfacing. *Facial Plast Surg Clin North Am*. 2005;13:127-139.
- Paasch U, Haedersdal M. Laser systems for ablative fractional resurfacing. *Expert Rev Med Devices*. 2011;8:67-83.
- Nanni CA, Alster TS. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. *Dermatol Surg*. 1998;24:315-320.
- Sripachya-Anunt S, Fitzpatrick RE, Goldman MP, et al. Infections complicating pulsed carbon dioxide laser resurfacing for photoaged facial skin. *Dermatol Surg*. 1997;23:527-535; discussion 535-536.
- Sachdev M, Hameed S, Mysore V. Nonablative lasers and nonlaser systems in dermatology: Current status. *Indian J Dermatol Venereol Leprol*. 2011;77:380-388.
- Weiss RA, McDaniel DH, Geronemus RG. Review of nonablative photorejuvenation: Reversal of the aging effects of the sun and environmental damage using laser and light sources. *Semin Cutan Med Surg*. 2003;22:93-106.
- Hardaway CA, Ross EV. Nonablative laser skin remodeling. *Dermatol Clin*. 2002;20:97-111, ix.
- Lee SY, Park KH, Choi JW, et al. A prospective, randomized, placebo-controlled, double-blinded, and split-face clinical study on LED pho-

- totherapy for skin rejuvenation: Clinical, profilometric, histologic, ultrastructural, and biochemical evaluations and comparison of three different treatment settings. *J Photochem Photobiol B Biol.* 2007;88:51-67.
34. Dierickx CC, Anderson RR. Visible light treatment of photoaging. *Dermatol Ther.* 2005;18:191-208.
 35. Weiss RA, Weiss MA, Geronemus RG, et al. A novel non-thermal non-ablative full panel LED photomodulation device for reversal of photoaging: Digital microscopic and clinical results in various skin types. *J Drugs Dermatol.* 2004;3:605-610.
 36. Weiss RA, McDaniel DH, Geronemus RG, et al. Clinical experience with light-emitting diode (LED) photomodulation. *Dermatol Surg.* 2005;31:1199-1205.
 37. Weiss RA, McDaniel DH, Geronemus RG, et al. Clinical trial of a novel non-thermal LED array for reversal of photoaging: Clinical, histologic, and surface profilometric results. *Lasers Surg Med.* 2005;36:85-91.
 38. Bhat J, Birch J, Whitehurst C, et al. A single-blinded randomised controlled study to determine the efficacy of Omnilux revive facial treatment in skin rejuvenation. *Lasers Med Sci.* 2005;20:6-10.
 39. Russell BA, Kellett N, Reilly LR. A study to determine the efficacy of combination LED light therapy (633 nm and 830 nm) in facial skin rejuvenation. *J Cosmet Laser Ther.* 2005;7:196-200.
 40. Barolet D, Roberge CJ, Auger FA, et al. Regulation of skin collagen metabolism in vitro using a pulsed 660 nm LED light source: Clinical correlation with a single-blinded study. *J Invest Dermatol.* 2009;129:2751-2759.
 41. Abergel RP, Lyons RF, Castel JC, et al. Biostimulation of wound healing by lasers: Experimental approaches in animal models and in fibroblast cultures. *J Dermatol Surg Oncol.* 1987;13:127-133.
 42. Yu W, Naim JO, Lanzafame RJ. The effect of laser irradiation on the release of bFGF from 3T3 fibroblasts. *Photochem Photobiol.* 1994;59:167-170.
 43. Schindl A, Heinze G, Schindl M, et al. Systemic effects of low-intensity laser irradiation on skin microcirculation in patients with diabetic microangiopathy. *Microvasc Res.* 2002;64:240-246.
 44. Ben-Dov N, Shefer G, Irintchev A, et al. Low-energy laser irradiation affects satellite cell proliferation and differentiation in vitro. *Biochim Biophys Acta.* 1999;1448:372-380.
 45. Kucuk BB, oral K, Selcuk NA, et al. The anti-inflammatory effect of low-level laser therapy on experimentally induced inflammation of rabbit temporomandibular joint retrodiscal tissues. *J Orofac Pain.* 2010;24:293-297.
 46. Geronemus RG, Weiss RA, Weiss MA, et al. Non-ablative LED photomodulation light activated fibroblast stimulation clinical trial. *Lasers Surg Med.* 2003;25:22.
 47. McDaniel DH, Newman J, Geronemus R, et al. Non-ablative non-thermal LED photomodulation—A multicenter clinical photoaging trial. *Lasers Surg Med.* 2003;15:22.
 48. Weiss RA, McDaniel DH, Geronemus R, et al. Non-ablative, non-thermal light emitting diode (LED) phototherapy of photoaged skin. *Lasers Surg Med.* 2004;16:31.
 49. Lee SY, You CE, Park MY. Blue and red light combination LED phototherapy for acne vulgaris in patients with skin phototype IV. *Lasers Surg Med.* 2007;39:180-188.
 50. Aziz-Jalali MH, Tabaie SM, Djavid GE. Comparison of red and infrared low-level laser therapy in the treatment of acne vulgaris. *Indian J Dermatol.* 2012;57:128-130.
 51. Rotunda AM, Bhupathy AR, Rohrer TE. The new age of acne therapy: Light, lasers, and radiofrequency. *J Cosmet Laser Ther.* 2004;6:191-200.
 52. Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. *Br J Dermatol.* 2000;142:855-856.
 53. Ross EV. Optical treatments for acne. *Dermatol Ther.* 2005;18:253-266.
 54. Sadick NS. Handheld LED array device in the treatment of acne vulgaris. *J Drugs Dermatol.* 2008;7:347-350.
 55. Goldberg DJ, Russell BA. Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris. *J Cosmet Laser Ther.* 2006;8:71-75.
 56. Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. *Br J Dermatol.* 2000;142:973-978.
 57. Sinha RP, Häder DP. UV-induced DNA damage and repair: A review. *Photochem Photobiol Sci.* 2002;1:225-236.
 58. Calles C, Schneider M, Macaluso F, et al. Infrared A radiation influences the skin fibroblast transcriptome: Mechanisms and consequences. *J Invest Dermatol.* 2010;130:1524-1536.
 59. Schroeder P, Calles C, Benesova T, et al. Photoprotection beyond ultraviolet radiation—Effective sun protection has to include protection against infrared A radiation-induced skin damage. *Skin Pharmacol Physiol.* 2010;23:15-17.
 60. Kimura E, Kawano Y, Todo H, et al. Measurement of skin permeation/penetration of nanoparticles for their safety evaluation. *Biol Pharm Bull.* 2012;35:1476-1486.
 61. Barolet D, Boucher A. LED photoprevention: Reduced MED response following multiple LED exposures. *Lasers Surg Med.* 2008;40:106-112.
 62. Krutmann J, Schroeder P. Role of mitochondria in photoaging of human skin: The defective powerhouse model. *J Invest Dermatol Symp Proc.* 2009;14:44-49.
 63. Menezes S, coulomb B, Lebreton C, et al. Non-coherent near infrared radiation protects normal human dermal fibroblasts from solar ultraviolet toxicity. *J Invest Dermatol.* 1998;111:629-633.
 64. Frank S, Oliver L, Lebreton-De Coster C, et al. Infrared radiation affects the mitochondrial pathway of apoptosis in human fibroblasts. *J Invest Dermatol.* 2004;123:823-831.
 65. Applegate LA, Scaletta C, Panizzon R, et al. Induction of the putative protective protein ferritin by infrared radiation: Implications in skin repair. *Int J Mol Med.* 2000;5:247-251.
 66. Yu HS, Wu CS, Yu CL, et al. Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. *J Invest Dermatol.* 2003;120:56-64.
 67. Yaar M, Grossman K, Eller M, et al. Evidence for nerve growth factor-mediated paracrine effects in human epidermis. *J Cell Biol.* 1991;115:821-828.
 68. Zhai S, Yaar M, Doyle SM, et al. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. *Exp Cell Res.* 1996;224:335-343.
 69. de Paula Eduardo C, Bezinelli LM, de Paula Eduardo F, et al. Prevention of recurrent herpes labialis outbreaks through low-intensity laser therapy: A clinical protocol with 3-year follow-up. *Lasers Med Sci.* 2012;27:1077-1083.
 70. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. *Clin Infect Dis.* 1998;26:541-553; quiz 554-555.
 71. Muñoz Sanchez PJ, Capote Femenías JL, Díaz Tejada A, et al. The effect of 670-nm low laser therapy on herpes simplex type 1. *Photomed Laser Surg.* 2012;30:37-40.
 72. Bello-Silva MS, de Freitas PM, Aranha AC, et al. Low- and high-intensity lasers in the treatment of herpes simplex virus 1 infection. *Photomed Laser Surg.* 2010;28:135-139.
 73. Schindl A, Neumann R. Low-intensity laser therapy is an effective treatment for recurrent herpes simplex infection. Results from a randomized double-blind placebo-controlled study. *J Invest Dermatol.* 1999;113:221-223.
 74. Landthaler M, Haina D, Waidelich W. [Treatment of zoster, post-zoster pain and herpes simplex recidivans in loco with laser light]. *Fortschr Med.* 1983;101:1039-1041.
 75. Perrin D, Jolivald JR, Triki H, et al. Effect of laser irradiation on latency of herpes simplex virus in a mouse model. *Pathol Biol (Paris).* 1997;45:24-27.
 76. Körner R, Bahmer F, Wigand R. The effect of infrared laser rays on herpes simplex virus and the functions of human immunocompetent cells. *Hautarzt.* 1989;40:350-354.
 77. Inoue K, Nishioka J, Hukuda S. Suppressed tuberculin reaction in guinea pigs following laser irradiation. *Lasers Surg Med.* 1989;9:271-275.
 78. Inoue K, Nishioka J, Hukuda S. Altered lymphocyte proliferation by low dosage laser irradiation. *Clin Exp Rheumatol.* 1989;7:521-523.

79. Yu W, Chi LH, Naim JO, et al. Improvement of host response to sepsis by photobiomodulation. *Lasers Surg Med.* 1997;21:262-268.
80. Schindl L, Schindl M, Polo L, et al. Effects of low power laser-irradiation on differential blood count and body temperature in endotoxin-preimmunized rabbits. *Life Sci.* 1997;60:1669-1677.
81. Manteifel V, Bakeeva L, Karu T. Ultrastructural changes in chondriome of human lymphocytes after irradiation with He-Ne laser: Appearance of giant mitochondria. *J Photochem Photobiol B.* 1997;38:25-30.
82. Bolton P, Young S, Dyson M. Macrophage responsiveness to light therapy: A dose response study. *Laser Ther.* 1990;2:101-106.
83. Funk JO, Kruse A, Kirchner H. Cytokine production after helium-neon laser irradiation in cultures of human peripheral blood mononuclear cells. *J Photochem Photobiol B.* 1992;16:347-355.
84. Yu HS, Chang KL, Yu CL, et al. Low-energy helium-neon laser irradiation stimulates interleukin-1 alpha and interleukin-8 release from cultured human keratinocytes. *J Invest Dermatol.* 1996;107:593-596.
85. Lee AY. Role of keratinocytes in the development of vitiligo. *Ann Dermatol.* 2012;24:115-125.
86. Yu R, Huang Y, Zhang X, et al. Potential role of neurogenic inflammatory factors in the pathogenesis of vitiligo. *J Cutan Med Surg.* 2012;16:230-244.
87. Kitamura R, Tsukamoto K, Harada K, et al. Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: Role of SCF/KIT protein interactions and the downstream effector, MITF-M. *J Pathol.* 2004;202:463-475.
88. Lan CC, Wu CS, Chiou MH, et al. Low-energy helium-neon laser induces melanocyte proliferation via interaction with type IV collagen: Visible light as a therapeutic option for vitiligo. *Br J Dermatol.* 2009;161:273-280.
89. Lan CC, Wu CS, Chiou MH, et al. Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: Recapitulation of vitiligo repigmentation in vitro. *J Invest Dermatol.* 2006;126:2119-2126.
90. Mandel AS, Dunaeva LP. Effect of laser therapy on blood levels of serotonin and dopamine scleroderma patients. *Vestn Dermatol Venerol.* 1982;8:13-17.
91. Mandel AS, Haberman HF, Pawlowski D, et al. Non PUVA nonsurgical therapies for vitiligo. *Clin Dermatol.* 1997;15:907-919.
92. Khullar SM, Brodin P, Barkvoll P, et al. Preliminary study of low-level laser for treatment of long-standing sensory aberrations in the inferior alveolar nerve. *J Oral Maxillofac Surg.* 1996;54:2-7; discussion 1997-1998.
93. Anders JJ, Borke RC, Woolery SK, et al. Low power laser irradiation alters the rate of regeneration of the rat facial nerve. *Lasers Surg Med.* 1993;13:72-82.
94. Rochkind S, Rousso M, Nissan M, et al. Systemic effects of low-power laser irradiation on the peripheral and central nervous system, cutaneous wounds, and burns. *Lasers Surg Med.* 1989;9:174-182.
95. Mandel AS. Skin repigmentation after laser therapy. *Vestn Dermatol Venerol.* 1984;9:26-29.
96. Yu HS. Treatment of vitiligo vulgaris with helium–neon laser. *MB Derma.* 2000;35:13-18.
97. Peacocke M, Yaar M, Mansur CP, et al. Induction of nerve growth factor receptors on cultured human melanocytes. *Proc Natl Acad Sci U S A.* 1988;85:5282-5286.
98. Wu CS, Lan CC, Chiou MH, et al. Basic fibroblast growth factor promotes melanocyte migration via increased expression of p125(FAK) on melanocytes. *Acta Derm Venereol.* 2006;86:498-502.
99. Morelli JG, Yohn JJ, Zekman T, et al. Melanocyte movement in vitro: Role of matrix proteins and integrin receptors. *J Invest Dermatol.* 1993;101:605-608.
100. Hedley SJ, Wagner M, Bielby S, et al. The influence of extracellular matrix proteins on cutaneous and uveal melanocytes. *Pigment Cell Res.* 1997;10:54-59.
101. Ma HJ, Zhu WY, Wang DG, et al. Endothelin-1 combined with extracellular matrix proteins promotes the adhesion and chemotaxis of amelanotic melanocytes from human hair follicles in vitro. *Cell Biol Int.* 2006;30:999-1006.
102. Ideta R, Soma T, Tsunenaga M, et al. Cultured human dermal papilla cells secrete a chemotactic factor for melanocytes. *J Dermatol Sci.* 2002;28:48-59.
103. Takano N, Kawakami T, Kawa Y, et al. Fibronectin combined with stem cell factor plays an important role in melanocyte proliferation, differentiation and migration in cultured mouse neural crest cells. *Pigment Cell Res.* 2002;15:192-200.
104. Gibson WT, Couchman JR, Weaver AC. Fibronectin distribution during the development of fetal rat skin. *J Invest Dermatol.* 1983;81:480-485.
105. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: Relevance to fibrotic skin diseases. *J Dermatol Sci.* 2000;24(Suppl 1):S60-S69.
106. Wolfram D, Tzankov A, Püzl P, et al. Hypertrophic scars and keloids—A review of their pathophysiology, risk factors, and therapeutic management. *Dermatol Surg.* 2009;35:171-181.
107. Bouzari N, Davis SC, Nouri K. Laser treatment of keloids and hypertrophic scars. *Int J Dermatol.* 2007;46:80-88.
108. Louw L. The keloid phenomenon: Progress toward a solution. *Clin Anat.* 2007;20:3-14.
109. Uitto J. IL-6 signaling pathway in keloids: A target for pharmacologic intervention?. *J Invest Dermatol.* 2007;127:6-8.
110. Ghazizadeh M, Tosa M, Shimizu H, et al. Functional implications of the IL-6 signaling pathway in keloid pathogenesis. *J Invest Dermatol.* 2007;127:98-105.
111. Liu W, Wang DR, Cao YL. TGF-beta: A fibrotic factor in wound scarring and a potential target for anti-scarring gene therapy. *Curr Gene Ther.* 2004;4:123-136.
112. Barolet D, Boucher A. Prophylactic low-level light therapy for the treatment of hypertrophic scars and keloids: A case series. *Lasers Surg Med.* 2010;42:597-601.
113. Hamblin MR, Demidova TN. Mechanisms of low level light therapy—An introduction. *Proc SPIE.* 2006;6140:61001-61012.
114. Ablon G. Combination 830-nm and 633-nm light-emitting diode phototherapy shows promise in the treatment of recalcitrant psoriasis: Preliminary findings. *Photomed Laser Surg.* 2010;28:141-146.

This Review is dedicated to the memory of our co-author, Dr. Zeev Pam, an outstanding dermatologist and an exceptionally smart, humble and kind person who passed away while this paper was being prepared for production. He was a great example to the people around him both professionally and personally. He will truly be missed.